Oppenheimer analyst Wendy Lam reiterated an Outperform rating and $162 price target on bluebird bio (NASDAQ: BLUE) following Q3 results.Lam ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View FDA

bluebird bio (BLUE) Post-ASH Abstract Sell-Off an 'Overreaction', Oppenheimer SaysNovember 5, 2015 11:00 AM bluebird bio (BLUE) Plunges 14% in Early Trade Following ASH UpdateNovember 5, 2015 8:20 AM bluebird bio (BLUE) Posts Wider-than-Expected Q3 LossNovember 5, 2015 6:45 AM bluebird bio Reports Third Quarter 2015 Financial Results and Recent Operational ProgressNovember 4, 2015 4:09 PM